Acamprosate Calcium
Brand Names: Campral
Methodology & AI Transparency ⓘ
Acamprosate Calcium Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Acamprosate calcium is indicated for the maintenance of abstinence from alcohol in patients with alcohol dependence who are abstinent at treatment initiation.
- 2 Real-world patient consensus: Tracked across 17 patient dosage logs with a 78% satisfaction benchmark (RxCUI 835726).
- 3 Typical cash cost range: 30-day cash pricing ranges from $20.76 on Cost Plus Drugs to $50.86 walk-in retail (NADAC $0.5859/unit).
- 4 Top reported side effects / signs: Most commonly reported Acamprosate Calcium tolerability events: nausea (11.2%), dizziness (9.1%), diarrhea (8.5%).
Ask our AI Specialists anything about Acamprosate Calcium
Acamprosate Calcium Mechanism, CYP450 Pathways & DailyMed Monograph
Acamprosate calcium is indicated for the maintenance of abstinence from alcohol in patients with alcohol dependence who are abstinent at treatment initiation. Treatment with acamprosate calcium should be part of a comprehensive management program that includes psychosocial support. The efficacy of acamprosate calcium in promoting abstinence has not been demonstrated in subjects who have not undergone detoxification and not achieved alcohol abstinence prior to beginning acamprosate calcium treatment.
12.1 Mechanism of Action The mechanism of action of acamprosate in maintenance of alcohol abstinence is not completely understood. Chronic alcohol exposure is hypothesized to alter the normal balance between neuronal excitation and inhibition. In vitro and in vivo studies in animals have provided evidence to suggest acamprosate may interact with glutamate and GABA neurotransmitter systems centrally, and has led to the hypothesis that acamprosate restores this balance.
Clinical clearance of Acamprosate Calcium (Alcohol Dependence Agent) relies on mixed metabolic conjugation and unchanged urinary excretion across acamprosate calcium regimens with a Terminal t½ estimated at 7–13 hrs depending on renal/hepatic reserve (Acamprosate Calcium) half-life; patients absorbing at F ≈ 49%–61% systemic availability after standard oral Acamprosate Calcium administration bioavailability typically observe target onset around time to peak concentration spans 1 to 3 hrs under acamprosate calcium maintenance.
FDA clinical labeling for Acamprosate Calcium restricts administration in acamprosate calcium is contraindicated in patients who previously have exhibited hypersensitivity to acamprosate calcium or any of its components (4.1).; acamprosate calcium is contraindicated in patients with severe renal impairment (4.2). across 333 mg/1 Tablet, Delayed Release, 333mg Tablet Delayed Release, with self-reported patient tracking dominated by nausea (11.2% of reports), dizziness (9.1% of reports), diarrhea (8.5% of reports).
Patients taking Acamprosate Calcium should avoid unmonitored CNS depressants due to compounded vigilance impairment.
Divalent and trivalent cations bind Acamprosate Calcium intraluminally and blunt peak oral plasma concentrations.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Acamprosate calcium is contraindicated in patients who previously have exhibited hypersensitivity to acamprosate calcium or any of its components (4.1).
- Acamprosate calcium is contraindicated in patients with severe renal impairment (4.2).
Logged Side-Effect Incidence (17 Reports)
Acamprosate Calcium Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Acamprosate Calcium)
Human clinical trial evidence for Acamprosate Calcium is indexed directly from the U.S. National Library of Medicine NCBI PubMed database. Explore recent randomized trials in the PubMed Research Pulse .
Acamprosate Calcium Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $0.5859/unit (~$17.58/30u) | Wholesale baseline |
| Mark Cuban Cost Plus Drugs (Mail-Order Generic) | Public Wholesale Price List (NADAC + 15% + pharmacy fee) | $20.76 / mo | Formulary listing ↗ |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $50.86 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 17 Anonymous DotMD Community Micro-Logs | $23.87 / mo | View logs ↓ |
| Sesame Direct Cash-Pay Prescriber Network (Licensed Telehealth Cash Program) | State-licensed clinician review • ~1d mail fulfillment | $29.00 consult | Program details |
| Virtual Psychiatric Medication Management (Licensed Telehealth Cash Program) | State-licensed clinician review • ~1d mail fulfillment | $39.00 consult | Program details |
Acamprosate Calcium Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Acamprosate Calcium RxNorm Concept ID | 835726 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $0.5859 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $50.86 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $20.76 / mo (Cost Plus Drugs) | Mark Cuban Cost Plus Public API |
| Real-World Patient Consensus | 78.00% Worth It (17 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Acamprosate Calcium Patient Community, Cohort Filters & Dosage Logs
Federal clinical ledger for Acamprosate Calcium integrating DailyMed SPL (2026-07-14), CMS NADAC ($0.5859/unit), and 17 Zero-PHI patient logs.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Acamprosate Calcium community threads and patient logs by age, biological sex, dosage, and treatment duration.